IL235358B - טריטוקואלין לשימוש בטיפול בסיסטיק פיברוזיס - Google Patents

טריטוקואלין לשימוש בטיפול בסיסטיק פיברוזיס

Info

Publication number
IL235358B
IL235358B IL235358A IL23535814A IL235358B IL 235358 B IL235358 B IL 235358B IL 235358 A IL235358 A IL 235358A IL 23535814 A IL23535814 A IL 23535814A IL 235358 B IL235358 B IL 235358B
Authority
IL
Israel
Prior art keywords
tritoqualine
treatment
cystic fibrosis
cystic
fibrosis
Prior art date
Application number
IL235358A
Other languages
English (en)
Other versions
IL235358A0 (he
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of IL235358A0 publication Critical patent/IL235358A0/he
Publication of IL235358B publication Critical patent/IL235358B/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL235358A 2012-04-30 2014-10-27 טריטוקואלין לשימוש בטיפול בסיסטיק פיברוזיס IL235358B (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305487.6A EP2659890A1 (en) 2012-04-30 2012-04-30 Methods and compositions for the treatment of fibrosis
PCT/EP2013/058158 WO2013164204A1 (en) 2012-04-30 2013-04-19 Tritoqualine for use in the treatment of cystic fibrosis

Publications (2)

Publication Number Publication Date
IL235358A0 IL235358A0 (he) 2014-12-31
IL235358B true IL235358B (he) 2019-09-26

Family

ID=48184183

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235358A IL235358B (he) 2012-04-30 2014-10-27 טריטוקואלין לשימוש בטיפול בסיסטיק פיברוזיס

Country Status (14)

Country Link
US (1) US9301955B2 (he)
EP (2) EP2659890A1 (he)
CA (1) CA2871815C (he)
CY (1) CY1117620T1 (he)
DK (1) DK2844253T3 (he)
ES (1) ES2569391T3 (he)
HR (1) HRP20160328T1 (he)
HU (1) HUE027353T2 (he)
IL (1) IL235358B (he)
PL (1) PL2844253T3 (he)
RS (1) RS54733B1 (he)
SI (1) SI2844253T1 (he)
SM (1) SMT201600102B (he)
WO (1) WO2013164204A1 (he)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
FR2990859B1 (fr) * 2012-05-24 2014-05-23 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
US10231932B2 (en) * 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
FR3015977B1 (fr) * 2013-12-30 2016-01-01 Patrice Binay Chlorhydrate de tritoqualine sous forme cristallisee et procede d'obtention
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
FR3048883B1 (fr) * 2016-03-18 2020-10-02 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la fibrose pulmonaire idiopathique
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
FR3109524B1 (fr) * 2020-04-22 2022-04-08 H4 Orphan Pharma Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales.
FR3111071B1 (fr) 2020-06-04 2023-01-13 H4 Orphan Pharma Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003023A1 (en) * 1986-10-31 1988-05-05 Mitsubishi Chemical Industries Limited Drug composition for treating liver diseases and process for its preparation
US20070238750A1 (en) 2006-04-07 2007-10-11 Michalis Nicolaou Pure isomers of tritoqualine
US8207188B2 (en) 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
EP2526938A3 (en) 2007-02-12 2013-06-12 Mike Nicolaou Histidine decarboxylase inhibitor sole or combined with a leukotriene receptor antagonist, an anti-H1 and/or an anti-H2 to treat COPD or gastrointestinal disorders.
AU2009259839A1 (en) 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions

Also Published As

Publication number Publication date
HUE027353T2 (en) 2016-09-28
PL2844253T3 (pl) 2016-09-30
US20150133487A1 (en) 2015-05-14
EP2659890A1 (en) 2013-11-06
EP2844253A1 (en) 2015-03-11
RS54733B1 (sr) 2016-10-31
CA2871815A1 (en) 2013-11-07
CA2871815C (en) 2019-12-24
EP2844253B1 (en) 2016-03-23
SI2844253T1 (sl) 2016-09-30
IL235358A0 (he) 2014-12-31
US9301955B2 (en) 2016-04-05
WO2013164204A1 (en) 2013-11-07
ES2569391T3 (es) 2016-05-10
SMT201600102B (it) 2016-07-01
HRP20160328T1 (hr) 2016-06-03
CY1117620T1 (el) 2017-04-26
DK2844253T3 (en) 2016-04-18

Similar Documents

Publication Publication Date Title
EP2968285A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
EP3698782C0 (en) CARBAMATE COMPOUNDS FOR USE IN THERAPY
IL235358A0 (he) טריטוקואלין לשימוש בטיפול בסיסטיק פיברוזיס
EP2730311A4 (en) FACIAL MASSAGE DEVICE
GB201120993D0 (en) Novel compounds and their use in therapy
IL260115A (he) שיטות לטיפול בפיברוזיס (לייפת)
PT2664326T (pt) Terapia combinada para a fibrose quística
IL227738B (he) תרכובת חדשה לטיפול בסיסטי פיברוזיס
GB201118704D0 (en) Cystic fibrosis treatment
EP2922536A4 (en) USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
HK1212340A1 (en) Substituted indazol pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
EP2817304A4 (en) NOVEL COMPOUNDS AND THEIR THERAPEUTIC USE
HUE039374T2 (hu) Kozmetikai alkalmazás
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
PL2875026T3 (pl) Pochodne imidazopirydyny stosowane w leczeniu cukrzycy
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
IL244829A0 (he) שימוש של אודיפרסיל לטיפול במוקופוליסכרידוזה
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
GB201000499D0 (en) Treatment of cystic fibrosis
GB201311713D0 (en) Cystic fibrosis treatment
ZA201505093B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis
AU2012900572A0 (en) Compositions and methods for the treatment of cystic fibrosis
PT2811993T (pt) Métodos de tratamento da fibrose
AU2012905072A0 (en) The use of bucillamine in the treatment of gout
GB201000571D0 (en) Treatment of cystic fibrosis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed